Intrathecal. administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury
Intrathecal. administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury
复制标题
DOI：
10.1016/j.neulet.2005.02.036
复制
发表时间：
2005-06-24
影响因子：
2.5
通讯作者：
Laskowitz, DT
中科院分区：
文献类型：
--
作者：
McAdoo, JD;Warner, DS;Laskowitz, DT
围产期缺氧缺血性脑损伤仍然是一个重要的临床问题，仍然没有足够的治疗干预。载脂蛋白E（apoE）是一种由299个氨基酸组成的蛋白质，已被证明可以改变急性缺血性和创伤性脑损伤后的功能恢复。当前研究的目的是评估给予apoE衍生肽是否可以减少围产期缺氧和缺血的啮齿动物模型中的中枢神经系统损伤。我们发现鞘内注射apoE模拟肽可显著减少缺血后脑坏死，这可通过缺氧缺血性损伤后7天同侧脑重量的减少来反映。这些结果表明，在围产期缺氧缺血性损伤的临床背景下，apoE衍生的治疗肽的管理代表了一种新的治疗策略。(c)2005爱思唯尔爱尔兰有限公司保留所有权利。
Perinatal hypoxic-ischemic brain injury remains a significant clinical problem for which there remains no adequate therapeutic intervention. Apolipoprotein E (apoE) is a 299 amino acid protein that has been demonstrated to modify functional recovery following acute ischemic and traumatic brain injury. The aim of the current study was to evaluate whether administration of an apoE-derived peptide could reduce CNS injury in a rodent model of perinatal hypoxia and ischemia. We found that intrathecal delivery of an apoE-mimetic peptide caused a significant reduction in post-ischemic brain necrosis, as reflected by decreased reduction in ipsilateral brain weight 7 days following hypoxic-ischemic injury. These results suggest that administration of an apoE-derived therapeutic peptide represents a novel therapeutic strategy in the clinical setting of perinatal hypoxic-ischemic injury. (c) 2005 Elsevier Ireland Ltd. All rights reserved.